RT Journal Article
SR Electronic
T1 Clopidogrel Resistance After Renal Transplantation
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 301
OP 303
VO 29
IS 2
A1 ADAM VARGA
A1 BARBARA SANDOR
A1 KAROLY KALMAR NAGY
A1 DORA PRAKSCH
A1 KATALIN GOMBOS
A1 ANDRAS TOTH
A1 KALMAN TOTH
A1 PETER SZAKALY
YR 2015
UL http://iv.iiarjournals.org/content/29/2/301.abstract
AB Background: Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenomenon; however, its causes are yet to be clarified. Patients and Methods: Forty post-transplant patients, who received 75 mg clopidogrel q.d. as a prophylactic measure, were examined using optical aggregometry. Subsequently, logistic regression analysis was performed with 24 variables in order to expose possible causes of resistance. Results: Sixty percent of patients (24) were resistant to clopidogrel therapy; effective thrombocyte inhibition could only be shown in 40% of them (16). Significant correspondence between resistance and variables could not be found. Conclusion: Clopidogrel resistance is expected to occur on a large scale in patients who underwent kidney transplant surgery. Thus, a key component of preventive therapy, which stresses the importance of discovering the cause of resistance so as to decrease mortality rates, is missing.